H.C. Wainwright maintained a neutral stance on Eyenovia (NASDAQ:EYEN) shares, reiterating a price target of $2.00. The firm's analyst, Matthew Caufield, highlighted the U.S. Food and Drug ...

Plymouth Industrial REIT, Inc. (NYSE: PLYM) is a full service, vertically integrated real estate investment company focused on the acquisition, ownership and management of single and multi-tenant ...

Rigorous testing has resulted in observations of the Optejet’s durable base unit performing over 30,000 sprays, and 98% of ...

Eyenovia (EYEN) announces recent progress on the development of its user-filled spray dispenser. “Millions of consumers have difficulty with ...

NEW YORK – Eyenovia, Inc., a pharmaceutical company specializing in preparations, announced today a reverse stock split of its common shares in a strategic move to comply with Nasdaq's minimum bid ...

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Eyenovia, Inc. (NASDAQ: EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet ...

The intelligent in-store audio platform is set to expand AI capabilities for audio ad creation, measurement and advanced ...

Eyenovia, Inc. announced on January 15, 2025, that leading proxy advisory firms ISS and Glass Lewis have advised stockholders to vote in favor of a proposed reverse stock split at a ratio between ...